Difference between revisions of "Gilteritinib (Xospata)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| Line 18: | Line 18: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' ASP-2215 |
*'''Brand name:''' Xospata | *'''Brand name:''' Xospata | ||
Latest revision as of 18:41, 14 August 2023
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Diseases for which it is used
History of changes in FDA indication
- 2018-11-28: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Based on ADMIRAL)
History of changes in EMA indication
- 2019-10-24: Initial authorization
History of changes in Health Canada indication
- 2019-12-23: Initial notice of compliance
History of changes in PMDA indication
- 2018-09-21: New approval for the treatment of relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
Patient Drug Information
Also known as
- Code name: ASP-2215
- Brand name: Xospata